Bristol-Myers Squibb Company (BMY)
NYSE: BMY · IEX Real-Time Price · USD
42.58
-0.06 (-0.14%)
Jul 22, 2024, 10:33 AM EDT - Market open
BMY Employees
Bristol-Myers Squibb Company had 34,100 employees as of December 31, 2023. The number of employees decreased by 200 or -0.58% compared to the previous year.
Employees
34,100
Change (1Y)
-200
Growth (1Y)
-0.58%
Revenue / Employee
$1,335,308
Profits / Employee
-$180,293
Market Cap
86.23B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34,100 | -200 | -0.58% |
Dec 31, 2022 | 34,300 | 2,100 | 6.52% |
Dec 31, 2021 | 32,200 | 1,950 | 6.45% |
Dec 31, 2020 | 30,250 | 250 | 0.83% |
Dec 31, 2019 | 30,000 | 6,700 | 28.76% |
Dec 31, 2018 | 23,300 | -400 | -1.69% |
Dec 31, 2017 | 23,700 | -1,300 | -5.20% |
Dec 31, 2016 | 25,000 | 0 | - |
Dec 31, 2015 | 25,000 | 0 | - |
Dec 31, 2014 | 25,000 | -3,000 | -10.71% |
Dec 31, 2013 | 28,000 | 0 | - |
Dec 31, 2012 | 28,000 | 1,000 | 3.70% |
Dec 31, 2011 | 27,000 | 0 | - |
Dec 31, 2010 | 27,000 | -1,000 | -3.57% |
Dec 31, 2009 | 28,000 | -7,000 | -20.00% |
Dec 31, 2008 | 35,000 | -7,000 | -16.67% |
Dec 31, 2007 | 42,000 | -1,000 | -2.33% |
Dec 31, 2006 | 43,000 | 0 | - |
Dec 31, 2005 | 43,000 | 0 | - |
Dec 31, 2004 | 43,000 | -1,000 | -2.27% |
Dec 31, 2003 | 44,000 | 0 | - |
Dec 31, 2002 | 44,000 | -2,000 | -4.35% |
Dec 31, 2001 | 46,000 | 2,000 | 4.55% |
Dec 31, 2000 | 44,000 | -10,500 | -19.27% |
Dec 31, 1999 | 54,500 | -200 | -0.37% |
Dec 31, 1998 | 54,700 | 1,100 | 2.05% |
Dec 31, 1997 | 53,600 | 2,400 | 4.69% |
Dec 31, 1996 | 51,200 | 2,060 | 4.19% |
Dec 31, 1995 | 49,140 | 1,440 | 3.02% |
Dec 31, 1994 | 47,700 | -1,800 | -3.64% |
Dec 31, 1993 | 49,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
HCA Healthcare | 310,000 |
CVS Health | 300,000 |
Medtronic | 95,000 |
Cigna | 72,500 |
GSK | 70,212 |
McKesson | 51,000 |
Boston Scientific | 48,000 |
Gilead Sciences | 18,000 |
BMY News
- 3 days ago - Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma - Business Wire
- 4 days ago - Bristol-Myers Squibb Reports On 7/26 - Options Expire The Same Day - Forbes
- 14 days ago - Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day - Business Wire
- 21 days ago - Bristol Myers to pay $2.7 mln to settle Israel anti-competition charges - Reuters
- 26 days ago - Will Bristol Myers Squibb Stock Rebound To Its 2022 Highs Of $80? - Forbes
- 4 weeks ago - Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) - Business Wire
- 4 weeks ago - US FDA approves Bristol Myers' colorectal cancer therapy - Reuters
- 4 weeks ago - European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab - Business Wire